Scroll
Statens Serum Institut

SSI concludes agreement with leading vaccine manufacturer concerning new tuberculosis test

 

Case

SSI concludes agreement with leading vaccine manufacturer concerning new tuberculosis test

Statens Serum Institut (SSI) has concluded an agreement with the Indian pharmaceutical group Serum Institute of India Pvt. Ltd. (SIIPL) concerning the commercialisation of a new test for diagnosing tuberculosis.

SIIPL is the world’s largest vaccine manufacturer. Their vaccines are accredited by the World Health Organization and are being used in national immunisation programs in 170 countries worldwide.

It is estimated that more than 1.5 billion people are infected with tuberculosis. Each year, close to 10 million of these people develop tuberculosis and 1.5 million die (source: Statens Serum Institut). The new test may help diagnosing the many people who are unknowingly infected with the pulmonary disease. The test is the first test for diagnosing tuberculosis which is reliable and effective without blood sampling and laboratory analyses.

SSI has developed the test which SIIPL is to produce and distribute. The test is expected to be ready for the market within the next 12 months.

Accura advised SSI in connection with the negotiations and the drafting of the agreement.

Read moreĀ here.